149 related articles for article (PubMed ID: 26072441)
1. Improving NCCN guideline-adherent care for ovarian cancer: Value of an intervention.
Dottino JA; Cliby WA; Myers ER; Bristow RE; Havrilesky LJ
Gynecol Oncol; 2015 Sep; 138(3):694-9. PubMed ID: 26072441
[TBL] [Abstract][Full Text] [Related]
2. Disparities in ovarian cancer care quality and survival according to race and socioeconomic status.
Bristow RE; Powell MA; Al-Hammadi N; Chen L; Miller JP; Roland PY; Mutch DG; Cliby WA
J Natl Cancer Inst; 2013 Jun; 105(11):823-32. PubMed ID: 23539755
[TBL] [Abstract][Full Text] [Related]
3. Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it?
Havrilesky LJ; Sanders GD; Kulasingam S; Myers ER
Gynecol Oncol; 2008 Nov; 111(2):179-87. PubMed ID: 18722004
[TBL] [Abstract][Full Text] [Related]
4. Adherence to treatment guidelines as a major determinant of survival disparities between black and white patients with ovarian cancer.
Chen F; Bailey CE; Alvarez RD; Shu XO; Zheng W
Gynecol Oncol; 2021 Jan; 160(1):10-15. PubMed ID: 33208254
[TBL] [Abstract][Full Text] [Related]
5. Reasons for failure to deliver National Comprehensive Cancer Network (NCCN)-adherent care in the treatment of epithelial ovarian cancer at an NCCN cancer center.
Erickson BK; Martin JY; Shah MM; Straughn JM; Leath CA
Gynecol Oncol; 2014 May; 133(2):142-6. PubMed ID: 24517876
[TBL] [Abstract][Full Text] [Related]
6. Spatial analysis of adherence to treatment guidelines for advanced-stage ovarian cancer and the impact of race and socioeconomic status.
Bristow RE; Chang J; Ziogas A; Anton-Culver H; Vieira VM
Gynecol Oncol; 2014 Jul; 134(1):60-7. PubMed ID: 24680770
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.
Havrilesky LJ; Pokrzywinski R; Revicki D; Higgins RV; Nycum LR; Kohler MF; Berchuck A; Myers ER; Secord AA
Cancer; 2012 Jan; 118(2):386-91. PubMed ID: 21598242
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the cost of CA-125 measurement, physical exam, and imaging in the diagnosis of recurrent ovarian cancer.
Armstrong A; Otvos B; Singh S; Debernardo R
Gynecol Oncol; 2013 Dec; 131(3):503-7. PubMed ID: 24060416
[TBL] [Abstract][Full Text] [Related]
9. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
[TBL] [Abstract][Full Text] [Related]
10. Socioeconomic status as a predictor of adherence to treatment guidelines for early-stage ovarian cancer.
Hodeib M; Chang J; Liu F; Ziogas A; Dilley S; Randall LM; Anton-Culver H; Bristow RE
Gynecol Oncol; 2015 Jul; 138(1):121-7. PubMed ID: 25913132
[TBL] [Abstract][Full Text] [Related]
11. Guideline adherence is worth the effort: a cost-effectiveness analysis in intrauterine insemination care.
Haagen EC; Nelen WL; Adang EM; Grol RP; Hermens RP; Kremer JA
Hum Reprod; 2013 Feb; 28(2):357-66. PubMed ID: 23202990
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Neoadjuvant Chemotherapy versus Primary Surgery in Elderly Patients with Advanced Ovarian Cancer.
Poonawalla IB; Lairson DR; Chan W; Piller LB; Du XL
Value Health; 2015 Jun; 18(4):387-95. PubMed ID: 26091592
[TBL] [Abstract][Full Text] [Related]
13. An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer.
Dalton HJ; Yu X; Hu L; Kapp DS; Benjamin I; Monk BJ; Chan JK
Gynecol Oncol; 2012 Feb; 124(2):199-204. PubMed ID: 22055763
[TBL] [Abstract][Full Text] [Related]
14. Rational prescribing in primary care (RaPP): economic evaluation of an intervention to improve professional practice.
Fretheim A; Aaserud M; Oxman AD
PLoS Med; 2006 Jun; 3(6):e216. PubMed ID: 16737349
[TBL] [Abstract][Full Text] [Related]
15. Population-Based Analysis of Patient Age and Other Disparities in the Treatment of Ovarian Cancer in Central Appalachia and Kentucky.
Ore RM; Chen Q; DeSimone CP; Miller RW; Baldwin LA; van Nagell JR; Huang B; Tucker TC; Johnson MS; Fredericks TI; Ueland FR
South Med J; 2018 Jun; 111(6):333-341. PubMed ID: 29863220
[TBL] [Abstract][Full Text] [Related]
16. Is It Time to Centralize Ovarian Cancer Care in the United States?
Cowan RA; O'Cearbhaill RE; Gardner GJ; Levine DA; Roche KL; Sonoda Y; Zivanovic O; Tew WP; Sala E; Lakhman Y; Vargas Alvarez HA; Sarasohn DM; Mironov S; Abu-Rustum NR; Chi DS
Ann Surg Oncol; 2016 Mar; 23(3):989-93. PubMed ID: 26511267
[TBL] [Abstract][Full Text] [Related]
17. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis.
Cohn DE; Kim KH; Resnick KE; O'Malley DM; Straughn JM
J Clin Oncol; 2011 Apr; 29(10):1247-51. PubMed ID: 21383297
[TBL] [Abstract][Full Text] [Related]
18. A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer.
Plamadeala V; Kelley JL; Chan JK; Krivak TC; Gabrin MJ; Brower SL; Powell MA; Rutherford TJ; Coleman RL
Gynecol Oncol; 2015 Jan; 136(1):94-8. PubMed ID: 25462203
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project.
Sović N; Pająk A; Jankowski P; Duenas A; Kawecka-Jaszcz K; Wolfshaut-Wolak R; Stepaniak U; Kawalec P
Kardiol Pol; 2013; 71(7):702-11. PubMed ID: 23907903
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer.
Lowery WJ; Lowery AW; Barnett JC; Lopez-Acevedo M; Lee PS; Secord AA; Havrilesky L
Gynecol Oncol; 2013 Sep; 130(3):426-30. PubMed ID: 23769759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
